{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:22:19Z","timestamp":1791145339242,"version":"4.1.0"},"reference-count":42,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.3892\/ijmm.2013.1302","type":"journal-article","created":{"date-parts":[[2013,3,13]],"date-time":"2013-03-13T11:33:17Z","timestamp":1363174397000},"page":"1273-1279","source":"Crossref","is-referenced-by-count":6,"title":["Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes"],"prefix":"10.3892","volume":"31","author":[{"given":"JANA","family":"POSPISILOVA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ONDREJ","family":"VIT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUCIE","family":"LORKOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAGDALENA","family":"KLANOVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAN","family":"ZIVNY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PAVEL","family":"KLENER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JIRI","family":"PETRAK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,3,13]]},"reference":[{"key":"key20180107233426_b1-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"key20180107233426_b2-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"key20180107233426_b3-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation","volume":"224","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"key20180107233426_b4-ijmm-31-05-1273","first-page":"5541S","article-title":"Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma","volume":"52","author":"Williams","year":"1992","journal-title":"Cancer Res"},{"key":"key20180107233426_b5-ijmm-31-05-1273","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2012.726719","article-title":"Current and emerging new treatment strategies for mantle cell lymphoma","author":"Humala","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"key20180107233426_b6-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"key20180107233426_b7-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J Biol Chem"},{"key":"key20180107233426_b8-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors: signaling and modulation","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"key":"key20180107233426_b9-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","article-title":"Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors","volume":"277","author":"Sheridan","year":"1997","journal-title":"Science"},{"key":"key20180107233426_b10-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrc821","article-title":"Targeting death and decoy receptors of the tumour-necrosis factor superfamily","volume":"2","author":"Ashkenazi","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"key20180107233426_b11-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1182\/blood-2011-08-370114","article-title":"Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL","volume":"119","author":"Castro Alves","year":"2012","journal-title":"Blood"},{"key":"key20180107233426_b12-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.cdd.4401186","article-title":"The CD95(APO-1\/Fas) DISC and beyond","volume":"10","author":"Peter","year":"2003","journal-title":"Cell Death Differ"},{"key":"key20180107233426_b13-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1369\/jhc.3A6112.2004","article-title":"Tissue distribution of the death ligand TRAIL and its receptors","volume":"52","author":"Spierings","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"key20180107233426_b14-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1002\/pmic.200900335","article-title":"Identification of molecular targets for selective elimination of TRAIL-resistant leukemia cells. From spots to in vitro assays using TOP15 charts","volume":"9","author":"Petrak","year":"2009","journal-title":"Proteomics"},{"key":"key20180107233426_b15-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/10428194.2012.710331","article-title":"Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis","volume":"54","author":"Molinsky","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"key20180107233426_b16-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bcmd.2008.10.002","article-title":"TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine","volume":"42","author":"Klener","year":"2009","journal-title":"Blood Cells Mol Dis"},{"key":"key20180107233426_b17-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4149\/neo_2013_030","article-title":"Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL)","volume":"60","author":"Leahomschi","year":"2013","journal-title":"Neoplasma"},{"key":"key20180107233426_b18-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V96.12.3900","article-title":"Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells","volume":"96","author":"Wen","year":"2000","journal-title":"Blood"},{"key":"key20180107233426_b19-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.leu.2402338","article-title":"TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors","volume":"16","author":"Plasilova","year":"2002","journal-title":"Leukemia"},{"key":"key20180107233426_b20-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"key20180107233426_b21-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcp.20099","article-title":"Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)\/Apo2L","volume":"201","author":"Di Pietro","year":"2004","journal-title":"J Cell Physiol"},{"key":"key20180107233426_b22-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180107233426_b23-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat Med"},{"key":"key20180107233426_b24-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/bbrc.1999.1693","article-title":"Locoregional Apo2L\/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity","volume":"265","author":"Roth","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107233426_b25-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"key20180107233426_b26-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1479-5876-3-22","article-title":"The anti-tumor effect of Apo2L\/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice","volume":"3","author":"Hylander","year":"2005","journal-title":"J Transl Med"},{"key":"key20180107233426_b27-ijmm-31-05-1273","first-page":"164","article-title":"On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics","author":"Dimberg","year":"2012","journal-title":"Oncogene"},{"key":"key20180107233426_b28-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in cancer","volume":"12","author":"Zhang","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"key20180107233426_b29-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12026-012-8284-8","article-title":"Resistance to TRAIL and how to surmount it","volume":"52","author":"Maksimovic-Ivanic","year":"2012","journal-title":"Immunol Res"},{"key":"key20180107233426_b30-ijmm-31-05-1273","first-page":"1326","article-title":"Purine and pyrimidine ribonucleoside monophosphate patterns of peripheral blood and bone marrow cells in human acute leukemias","volume":"42","author":"Scavennec","year":"1982","journal-title":"Cancer Res"},{"key":"key20180107233426_b31-ijmm-31-05-1273","first-page":"2475","article-title":"Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues","volume":"44","author":"Natsumeda","year":"1984","journal-title":"Cancer Res"},{"key":"key20180107233426_b32-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2215\/CJN.02320312","article-title":"Adenine phosphoribosyltransferase deficiency","volume":"7","author":"Bollee","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20180107233426_b33-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1567-5769(01)00056-X","article-title":"Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - a novel potent and orally active immunosuppressive agent","volume":"1","author":"Bantia","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"key20180107233426_b34-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0162-3109(96)00123-3","article-title":"In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP","volume":"35","author":"Bantia","year":"1996","journal-title":"Immunopharmacology"},{"key":"key20180107233426_b35-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.2174\/092986708784221449","article-title":"Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy","volume":"15","author":"Galmarini","year":"2008","journal-title":"Curr Med Chem"},{"key":"key20180107233426_b36-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"key20180107233426_b37-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1021\/cr900021w","article-title":"IMP dehydrogenase: structure, mechanism, and inhibition","volume":"109","author":"Hedstrom","year":"2009","journal-title":"Chem Rev"},{"key":"key20180107233426_b38-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3420143","article-title":"Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?","volume":"342","author":"Fairbanks","year":"1999","journal-title":"Biochem J"},{"key":"key20180107233426_b39-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00192309","article-title":"The design and development of an immunosuppressive drug, mycophenolate mofetil","volume":"14","author":"Allison","year":"1993","journal-title":"Springer Semin Immunopathol"},{"key":"key20180107233426_b40-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0042-6822(03)00152-1","article-title":"The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA","volume":"310","author":"Zhou","year":"2003","journal-title":"Virology"},{"key":"key20180107233426_b41-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2005-03-1309","article-title":"A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)","volume":"106","author":"Gandhi","year":"2005","journal-title":"Blood"},{"key":"key20180107233426_b42-ijmm-31-05-1273","doi-asserted-by":"crossref","first-page":"8615","DOI":"10.1021\/bi980658d","article-title":"One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase","volume":"37","author":"Miles","year":"1998","journal-title":"Biochemistry"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijmm.2013.1302\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:26:02Z","timestamp":1745972762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2013.1302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,13]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,3,13]]},"published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.3892\/ijmm.2013.1302"],"URL":"https:\/\/doi.org\/10.3892\/ijmm.2013.1302","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,13]]}}}